From the Centers for Disease Control and Prevention. Update: Investigation of bioterrorism-related anthrax and interim guidelines for exposure management and antimicrobial therapy, October 2001

JAMA. 2001 Nov 14;286(18):2226-32. doi: 10.1001/jama.286.18.2226.
No abstract available

Publication types

  • Guideline

MeSH terms

  • Adult
  • Anthrax* / diagnosis
  • Anthrax* / drug therapy
  • Anthrax* / epidemiology
  • Anthrax* / prevention & control
  • Anti-Bacterial Agents / therapeutic use
  • Antibiotic Prophylaxis
  • Bacillus anthracis / drug effects
  • Bacillus anthracis / genetics
  • Bacillus anthracis / isolation & purification*
  • Bioterrorism*
  • Child
  • Ciprofloxacin / therapeutic use
  • District of Columbia / epidemiology
  • Doxycycline / therapeutic use
  • Female
  • Florida / epidemiology
  • Government Agencies
  • Humans
  • Male
  • Maryland / epidemiology
  • Microbial Sensitivity Tests
  • Middle Aged
  • New Jersey / epidemiology
  • New York / epidemiology
  • Occupational Exposure / prevention & control
  • Postal Service
  • Public Health Practice*
  • Respiratory Tract Infections* / diagnosis
  • Respiratory Tract Infections* / drug therapy
  • Respiratory Tract Infections* / epidemiology
  • Respiratory Tract Infections* / prevention & control
  • Skin Diseases, Bacterial* / diagnosis
  • Skin Diseases, Bacterial* / drug therapy
  • Skin Diseases, Bacterial* / epidemiology
  • Skin Diseases, Bacterial* / prevention & control
  • Spores, Bacterial / isolation & purification*
  • United States / epidemiology
  • Virginia / epidemiology

Substances

  • Anti-Bacterial Agents
  • Ciprofloxacin
  • Doxycycline